1. Home
  2. RCG vs TOVX Comparison

RCG vs TOVX Comparison

Compare RCG & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RCG

RENN Fund Inc

HOLD

Current Price

$2.76

Market Cap

18.1M

Sector

Finance

ML Signal

HOLD

TOVX

Theriva Biologics Inc.

HOLD

Current Price

$0.37

Market Cap

16.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RCG
TOVX
Founded
N/A
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.1M
16.4M
IPO Year
1996
2012

Fundamental Metrics

Financial Performance
Metric
RCG
TOVX
Price
$2.76
$0.37
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$1.00
AVG Volume (30 Days)
7.2K
22.8M
Earning Date
01-01-0001
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
89.07
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.40
$0.16
52 Week High
$3.31
$0.86

Technical Indicators

Market Signals
Indicator
RCG
TOVX
Relative Strength Index (RSI) 39.63 59.15
Support Level $2.48 $0.18
Resistance Level $3.00 $0.52
Average True Range (ATR) 0.06 0.04
MACD -0.01 -0.00
Stochastic Oscillator 27.15 48.06

Price Performance

Historical Comparison
RCG
TOVX

About RCG RENN Fund Inc

RENN Fund Inc is active in the financial services domain. It is a a registered, non-diversified, closed-end management investment company formed to provide return through capital appreciation and income by a long-term, value-oriented investment process that invests in a wide variety of financial instruments, including but not limited to, common stocks, fixed-income securities including convertible and non-convertible debt securities or loans, distressed debt, warrants, and preferred stock, exchange-traded funds and exchange-traded notes, and other instruments. It invests in various industries, including communication services, surgical and medical instruments and apparatus, oil and gas, medical chemicals, botanical products, etc.

About TOVX Theriva Biologics Inc.

Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.

Share on Social Networks: